Diabetic Nephropathy - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 239 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Nephropathy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H1 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Nephropathy Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Nephropathy - Overview 11
Pipeline Products for Diabetic Nephropathy - Comparative Analysis 12
Diabetic Nephropathy - Therapeutics under Development by Companies 13
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 18
Diabetic Nephropathy - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Diabetic Nephropathy - Products under Development by Companies 23
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 27
Diabetic Nephropathy - Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Aerpio Therapeutics, Inc. 29
Antisense Therapeutics Limited 30
Astellas Pharma Inc. 31
AstraZeneca PLC 32
Bayer AG 33
Bristol-Myers Squibb Company 34
Cellmid Limited 35
ChemoCentryx, Inc. 36
Concert Pharmaceuticals, Inc. 37
CTI BioPharma Corp. 38
Daiichi Sankyo Company, Limited 39
DiaMedica Inc. 40
Dimerix Bioscience Pty Ltd 41
Dong Wha Pharma Co., Ltd. 42
Eli Lilly and Company 43
Galectin Therapeutics, Inc. 44
GenKyoTex S.A. 45
Gentium S.p.A. 46
Gilead Sciences, Inc. 47
GlaxoSmithKline plc 48
Glucox Biotech AB 49
GNI Group Ltd. 50
IMMD Inc. 51
Intercept Pharmaceuticals, Inc. 52
InterMune, Inc. 53
Inventiva SAS 54
Islet Sciences, Inc. 55
Jenrin Discovery, Inc. 56
Johnson & Johnson 57
Mallinckrodt plc 58
Mesoblast Limited 59
Mitsubishi Tanabe Pharma Corporation 60
NephroGenex, Inc. 61
Noxxon Pharma AG 62
Omeros Corporation 63
OncoImmune, Inc. 64
Otsuka Holdings Co., Ltd. 65
Pfizer Inc. 66
PhytoHealth Corporation 67
ProMetic Life Sciences Inc. 68
Serodus ASA 69
Shire Plc 70
Thrasos, Inc. 71
Torrent Pharmaceuticals Limited 72
Vascular Pharmaceuticals, Inc. 73
Diabetic Nephropathy - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Target 75
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
11-RVIVIT - Drug Profile 85
A-717 - Drug Profile 86
APX-115 - Drug Profile 87
ASP-7657 - Drug Profile 88
ASP-8232 - Drug Profile 89
ATL-1103 - Drug Profile 90
atrasentan hydrochloride - Drug Profile 92
baricitinib - Drug Profile 94
BMS-813160 - Drug Profile 97
canagliflozin - Drug Profile 98
CCX-140 - Drug Profile 100
corticotropin - Drug Profile 102
CS-3150 - Drug Profile 104
CTP-499 - Drug Profile 106
Cyndacel-M - Drug Profile 108
DCB-DN1 - Drug Profile 109
DM-199 - Drug Profile 110
DMX-250 - Drug Profile 112
Drug for Diabetic Nephropathy - Drug Profile 113
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy - Drug Profile 114
DT-23552 - Drug Profile 115
DW-1029M - Drug Profile 116
emapticap pegol - Drug Profile 117
finerenone - Drug Profile 119
GKT-136901 - Drug Profile 120
GKT-137831 - Drug Profile 122
GKT-901 - Drug Profile 123
GR-MD-02 - Drug Profile 124
GS-4997 - Drug Profile 126
GW-610742 - Drug Profile 127
hu-91 - Drug Profile 129
IMD-1041 - Drug Profile 131
INT-767 - Drug Profile 132
JD-5037 - Drug Profile 134
JNJ-39933673 - Drug Profile 135
KBP-5074 - Drug Profile 136
lisofylline - Drug Profile 137
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 139
Monoclonal Antibody to Inhibit HPTPbeta for Diabetic Nephropathy - Drug Profile 141
Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders - Drug Profile 142
MSC300-IV - Drug Profile 143
MT-3995 - Drug Profile 145
Nephrilin - Drug Profile 146
Oligotide - Drug Profile 147
OX-029 - Drug Profile 149
PBI-4050 - Drug Profile 150
PF-00489791 - Drug Profile 151
PF-04634817 - Drug Profile 152
PF-06409577 - Drug Profile 153
PHN-033 - Drug Profile 154
pirfenidone - Drug Profile 155
pirfenidone - Drug Profile 158
probucol - Drug Profile 160
Pyridoxamine Dihydrochloride - Drug Profile 161
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 163
SER-150 - Drug Profile 164
SHP-627 - Drug Profile 166
Small Molecule for Diabetic Nephropathy - Drug Profile 167
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 168
Small Molecules for Diabetic Nephropathy - Drug Profile 169
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 170
SP-20202 - Drug Profile 172
THRV-123 - Drug Profile 173
TRC-120038 - Drug Profile 174
VPI-2690-B - Drug Profile 175
Diabetic Nephropathy - Recent Pipeline Updates 177
Diabetic Nephropathy - Dormant Projects 224
Diabetic Nephropathy - Discontinued Products 226
Diabetic Nephropathy - Product Development Milestones 227
Featured News & Press Releases 227
Appendix 234
Methodology 234
Coverage 234
Secondary Research 234
Primary Research 234
Expert Panel Validation 234
Contact Us 234
Disclaimer 235

List of Tables
Number of Products under Development for Diabetic Nephropathy, H1 2015 15
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Comparative Analysis by Unknown Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2015 31
Diabetic Nephropathy - Pipeline by AbbVie Inc., H1 2015 32
Diabetic Nephropathy - Pipeline by Aerpio Therapeutics, Inc., H1 2015 33
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H1 2015 34
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H1 2015 35
Diabetic Nephropathy - Pipeline by AstraZeneca PLC, H1 2015 36
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2015 37
Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Company, H1 2015 38
Diabetic Nephropathy - Pipeline by Cellmid Limited, H1 2015 39
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2015 40
Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41
Diabetic Nephropathy - Pipeline by CTI BioPharma Corp., H1 2015 42
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43
Diabetic Nephropathy - Pipeline by DiaMedica Inc., H1 2015 44
Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 45
Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 46
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H1 2015 47
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H1 2015 48
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H1 2015 49
Diabetic Nephropathy - Pipeline by Gentium S.p.A., H1 2015 50
Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H1 2015 51
Diabetic Nephropathy - Pipeline by GlaxoSmithKline plc, H1 2015 52
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H1 2015 53
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H1 2015 54
Diabetic Nephropathy - Pipeline by IMMD Inc., H1 2015 55
Diabetic Nephropathy - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 56
Diabetic Nephropathy - Pipeline by InterMune, Inc., H1 2015 57
Diabetic Nephropathy - Pipeline by Inventiva SAS, H1 2015 58
Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H1 2015 59
Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H1 2015 60
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2015 61
Diabetic Nephropathy - Pipeline by Mallinckrodt plc, H1 2015 62
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H1 2015 63
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 64
Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H1 2015 65
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2015 66
Diabetic Nephropathy - Pipeline by Omeros Corporation, H1 2015 67
Diabetic Nephropathy - Pipeline by OncoImmune, Inc., H1 2015 68
Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 69
Diabetic Nephropathy - Pipeline by Pfizer Inc., H1 2015 70
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H1 2015 71
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H1 2015 72
Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2015 73
Diabetic Nephropathy - Pipeline by Shire Plc, H1 2015 74
Diabetic Nephropathy - Pipeline by Thrasos, Inc., H1 2015 75
Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 76
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H1 2015 77
Assessment by Monotherapy Products, H1 2015 78
Number of Products by Stage and Target, H1 2015 80
Number of Products by Stage and Mechanism of Action, H1 2015 83
Number of Products by Stage and Route of Administration, H1 2015 86
Number of Products by Stage and Molecule Type, H1 2015 88
Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H1 2015 181
Diabetic Nephropathy - Dormant Projects, H1 2015 228
Diabetic Nephropathy - Dormant Projects (Contd..1), H1 2015 229
Diabetic Nephropathy - Discontinued Products, H1 2015 230